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AbstrACt
Objectives Informed decisions about cancer screening 
require accurate knowledge regarding cancer risks and 
screening. This study investigates: (1) European women’s 
knowledge of their risk of developing breast, ovarian, 
cervical or endometrial cancer, (2) their knowledge about 
mammography screening and (3) whether an evidence-
based leaflet improves their knowledge.
Design Cross-sectional online intervention survey.
setting National samples from five European countries 
(Czech Republic, Germany, UK, Italy and Sweden)—
drawn from the Harris Interactive and the Toluna panel, 
respectively, in January 2017—were queried on their 
knowledge of age-specific risks of developing breast, 
cervical, ovarian or endometrial cancer within the next 10 
years and of mammography screening before and after 
intervention.
Participants Of 3629 women (inclusion criteria: age 40–
75 years) invited, 2092 responded and 1675 completed 
the survey (response rate: 61.4%).
Intervention Evidence-based leaflet summarising 
information on age-adjusted female cancer risks, 
mammography and aspects of cancer prevention.
Primary outcome measures Proportion of women (1) 
accurately estimating their risk of four female cancers, (2) 
holding correct assumptions of mammography screening 
and (3) changing their estimations and assumptions after 
exposure to leaflet.
Findings Across countries, 59.2% (95% CI 56.8% to 
61.6%) to 91.8% (95% CI 90.3% to 93.0%) overestimated 
their female cancer risks 7–33 fold (mediansacross tumours: 
50.0 to 200.0). 26.5% (95% CI 24.4% to 28.7%) were 
aware that mammography screening has both benefits 
and harms. Women who accurately estimated their breast 
cancer risk were less likely to believe that mammography 
prevents cancer (p<0.001). After leaflet intervention, 
knowledge of cancer risks improved by 27.0 (95% CI 24.9 
to 29.2) to 37.1 (95% CI 34.8 to 39.4) percentage points 
and of mammography by 23.0 (95% CI 21.0 to 25.1) 
percentage points.
Conclusion A considerable number of women in five 
European countries may not possess the prerequisites for 
an informed choice on cancer screening. Evidence-based 
information in patient leaflets can improve this situation.
IntrODuCtIOn 
Women in countries with modern healthcare 
systems are confronted with the question of 
whether to participate in screening for female 
cancers (ie, breast cancer, cervical cancer, 
ovarian cancer and endometrial cancer). 
Cancer screening can produce benefits by 
identifying treatable cancer at an early stage 
and thereby reducing the risk of mortality. 
Cancer screening can, however, also produce 
harms by overdiagnosis and overtreatment.1 2 
Overdiagnosis is the detection of histopatho-
logical abnormalities that meet the definition 
of (pre-)cancer but would never progress to 
strengths and limitations of this study
 ► Our study is, to the best of our knowledge, the first 
systematic investigation in five European countries 
of women’s estimates of their age-specific risk for 
breast, ovarian, cervical and endometrial cancer; 
their basic understanding of mammography screen-
ing; the link between their cancer risk perception 
and their understanding of screening; and the ex-
tent to which their knowledge would benefit from 
the provision of evidence-based health information.
 ► Due to the cross-sectional design of the study, we 
were unable to assess whether the improved out-
comes after intervention translated into any be-
havioural changes or were maintained over the 
longer run.
 ► We also cannot exclude the likelihood that women 
with a greater interest in the topic of cancer and 
screening were more likely to respond to our survey, 
which might have influenced our results and limit 
generalisability.
2 Wegwarth O, et al. BMJ Open 2018;8:e023789. doi:10.1136/bmjopen-2018-023789
Open access 
an invasive cancer that causes cancer-specific symptoms 
or death.2 3 The consequence of overdiagnosis is over-
treatment, that is, unnecessary surgery, chemotherapy 
or radiation that does not benefit the patient but only 
harms. The proportion of benefits and harms varies by 
the basic risk of cancer type and screening programme4–8; 
thus, this information needs to be made available to the 
public to allow informed decisions.9 10 Efforts to increase 
mortality benefits and reduce the extent of overdiagnosis 
by stratifying cancer screening according to risks are now 
underway and make the need for communicating the 
basic cancer risks even more apparent.11 
To date, screening for endometrial cancer is neither 
encouraged nor recommended by any European country 
because evidence endorsing the screening is lacking. 
Likewise, population-based ovarian cancer screening 
using ultrasound is not recommended because current 
evidence demonstrates an unfavourable balance of 
its benefits and harms.4 12 New strategies assigning women 
to multimodal screening using blood-based tumour-
marker dynamical changes12 might prove to be  poten-
tially (cost-)effective in the future and become a feasible 
screening tool for this type of cancer.13 In contrast, 
nearly all European countries have established popula-
tion-based screening programmes for breast and cervical 
cancer on the basis of evidence demonstrating that the 
benefit–harm ratio is sufficiently balanced for certain 
age groups.7 14 Particularly for mammography screening, 
European women between 50 and 69 years receive regu-
larly invitation letters for participating in the screening 
and informational material about the effectiveness of the 
screening.
But are women sufficiently informed about the their 
baseline cancer risk and the benefits and harms of 
mammography screening, which is a prerequisite to 
making an informed choice on screening attendance? 
In nine European countries, 92% of the women overesti-
mated the benefit of mammography by at least an order 
of magnitude, and less than 10% of a national US sample 
regularly attending one or more cancer screenings had 
ever heard of overdiagnosis due to screening.15 16 The 
European study additionally revealed that the nature of 
health information provided largely influenced overes-
timation. Moreover, as a German national study docu-
mented, a considerable number of women incorrectly 
assumed that mammography screening prevents inci-
dence of cancer.17 What remains unaddressed in these 
studies is whether these women had already greatly over-
estimated their risk of developing cancer at a certain 
time in life. Misperceiving one’s own risk of developing 
cancer as being particularly high may trigger unreason-
able assumptions about cancer screening.15 17
This study addresses five main questions: (1) do Euro-
pean women know their risk of being diagnosed with 
breast, ovarian, cervical or endometrial cancer?; (2) do 
European women know that cancer screening such as 
mammography has both benefit and harms and does 
this knowledge correspond with their knowledge of their 
breast cancer risk?; (3) are European women in the core 
age group of breast cancer screening more likely to have 
more accurate knowledge regarding breast cancer risks 
and mammography screening?; (4) does an information 
leaflet improve European women’s knowledge regarding 
cancer risk and screening?; and (5) do women from 
different European countries vary in their knowledge 
before and after the intervention?
MethOD
The core objectives of this study were triggered by the 
requirements of the ongoing Female cancer predic-
tion using cervical omics to individualise screening and 
prevention (FORECEE) project— funded by the Euro-
pean Union’s Horizon 2020 research and innovation 
programme—that aims to develop an epigenetic test to 
predict the risk for breast, ovarian, cervical and endo-
metrial cancers in women using cervical cells (https:// 
forecee. eu). Part of the FORECEE project is to understand 
educational and communicative needs from the side of 
women who might be targeted by the potential introduc-
tion of the resulting women’s cancer risks identification 
(WID) test in the future. The study reported herein inves-
tigated the educational aspect in that it sought to learn: 
(1) about women’s knowledge of their female cancer 
risks and cancer screening at base line and (2) about the 
effect of an evidence-based leaflet (intervention) on that 
knowledge. To gain these insights with sufficiently large 
national samples from different European countries, the 
study was set up as a cross-sectional online survey with 
two phases (before/after intervention). The content of 
the cross-sectional online intervention survey and an 
evidence-based leaflet (intervention) were developed 
by the authors of the study; revised by clinical, epidemi-
ological and decision analysis experts of the FORECEE 
consortium; and programmed by the market research 
institute Harris Interactive (Germany). Study materials 
were translated into country-specific languages by a 
professional translation office and checked for correct-
ness and completeness by country-specific members of 
the FORECEE consortium.
sample frame
The sample frame was the Harris Interactive Panel 
and the Toluna Panel, maintained and subcontracted, 
respectively, by Harris Interactive, an established market 
research institute operating in more than 60 countries 
worldwide. The panels are representative of the general 
population with respect to age, education, gender and 
regions in each of the countries and comprise about 
78 000 and 275 000 female participants of the age group 
targeted in this study, respectively. Participants have 
agreed in advance to participate in online research.
sample selection
The survey questions targeted knowledge on cancer 
screening and female cancer risks in European women. 
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Thus, the goal was to survey national samples of 
women in and around the core age group of screening 
programmes (40–75 years) in five European countries 
that represent Northern, Eastern, Southern, Western and 
Central Europe and the nationalities of members of the 
FORECEE consortium. The countries chosen based on 
these criteria were: the Czech Republic, Germany, the 
UK, Italy and Sweden. To reduce non-respondent bias 
and to better reflect the general population of women 
at screening age in each country, we applied quotas 
matching the distribution of age and education of the 
general population of each country at the point of survey 
completion. Quotas per country were calculated on the 
grounds of three levels of education (low, medium and 
high) as categorised by the International Standard Clas-
sification of Education (ISCED) and of four age groups 
(40–49 years, 50-59 years, 60–69 years and 70–75 years). 
We calculated that a sample size of 300 participants per 
country was required to detect differences in knowledge 
of 20% or higher within and between samples. To allow 
for non-response and ineligibility, Harris eventually drew 
a sample of 3629 women from the panels.
survey administration
In January 2017, Harris Interactive contacted eligible 
women in each of the five European countries by email. 
The email provided basic information about the study, 
the link to the study (with a personalised password) in 
the nation-specific language of the target population and 
an offer of a €5 honorarium on completion of the survey. 
Up to two reminder emails were sent to non-respondents 
until the intended sample size was met.
survey questionnaire and intervention
The survey study comprised a leaflet intervention and 
two main questions concerning female cancer risks and 
screening knowledge, which were asked before and after 
the intervention. For the question on female cancer risks, 
women were asked to provide their numerical estimates 
(open-field response) of how many women out of 1000 
in her specific age group will be diagnosed with each of 
the following four listed female cancers (breast, ovarian, 
cervical and endometrial cancer) within the next 10 
years. The order of cancer types was always randomised. 
Next, they were asked whether cancer screening such as 
mammography: (1) comes with benefits (reduction of 
cancer deaths) but no harms, (2) comes with benefits 
(reduction of cancer deaths) and harms (eg, overdiag-
nosis) or (3) helps prevent cancer before it starts. Again, 
the order of the possible answers was always randomised. 
After responding to the questions, women were next 
presented online with the leaflet intervention. Women 
were not told that they would be later queried on the 
same questions again and, after opening the leaflet 
online, were no longer able to return to the initial part 
of the survey.
The leaflet was developed at early stages together with 
focus groups of women at target age and was based on 
the guideline for evidence-based health information of 
the German Network for Evidence-Based Medicine,18 
which recommends informing people about the actual 
risk of a specific disease in question, informing them 
about potential interventions by using absolute numbers 
and the same reference class when describing the benefit 
and harms and setting this benefit–harm information in 
context with the option of doing nothing if applicable. 
Accordingly, the leaflet informed women on age-spe-
cific risks (45 years, 55 years, 65 years and 75 years) for 
breast, ovarian, cervical and endometrial cancer in the 
general population over a period of 10 years; on current 
approaches of cancer screening—exemplified in detail 
for mammography screening—and prevention; and on 
the benefit–harm ratio of populations attending or not 
attending mammography screening based on current 
evidence19 and exemplified in a facts box,20 21 which has 
been shown to improve understanding even in people 
with low literacy levels.22 Women could take as much time 
as they desired to familiarise themselves with the content 
of the leaflet. After they finished reading the leaflet by 
clicking the next button, women were presented with the 
initial questions again and no longer able to return to the 
leaflet. The exact wording of the survey and leaflet can be 
seen in the online supplementary file.
The leaflet was part of a larger study on: (1) women’s 
knowledge about female cancers and cancer screening 
and (2) their attitude towards a forthcoming epigenetic 
predictive test on female cancer risks (WID test). Results 
from the second part of the study, which do not deal with 
women’s knowledge of current risk and clinical practice, 
go beyond the scope of this article and will be presented 
elsewhere.
Outcomes
The primary outcomes were the: (1) proportion of women 
accurately estimating their risk of four female cancers, (2) 
proportion of women holding correct assumptions about 
mammography screening and (3) proportional changes 
in these estimations and assumptions after exposure to 
the leaflet. The secondary outcomes were: (1) differences 
in the proportion of correct judgements between the five 
European countries, (2) differences in this proportion 
between women belonging and not belonging to the core 
age group (50–69 years) of systematic mammography 
screening and (3) the association between an accurate 
estimation of breast cancer risk and misconceptions of 
mammography.
statistical analysis and data presentation
The online version of the questionnaire did not allow 
for item non-response; thus, all 1675 questionnaires were 
completed in full. Epidemiological data on age-specific 
10-year risks for each of the female cancers were derived 
from the population-based cancer registry database 
of the Robert Koch Institute ( www. krebsdaten. de) in 
Germany.23 Details on the age-specific risks for each of 
the four female cancers derived from the database can 
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be seen in table 1. To accommodate for potential coun-
try-specific variations in female cancer risks, women’s 
responses to the knowledge questions on female cancer 
risks were rated correctly within a ±50% margin of error. 
For instance, if the risk of a 55-year-old woman devel-
oping breast cancer within the next 10 years was 30 
out of 1000 women, estimates between 15 and 45 were 
considered correct. Estimates above the upper bound of 
the 50% margin of error were rated as ‘overestimations’ 
and those below the lower bound of the 50% margin as 
‘underestimations’. Women’s responses to the question 
concerning their knowledge of mammography screening 
were rated correct if they chose the option stating that 
the screening comes with benefits (reduction of cancer 
deaths) and harms (eg, overdiagnosis), as suggested 
by scientific evidence.7 19 Because a personal history of 
female cancer may have influenced women’s estimates 
of their personal female cancer risk, we analysed all data 
including and excluding the 129 women who reported a 
personal history of female cancer or were unsure about 
their past diagnosis. These analyses showed no effect on 
the outcome measures reported here, which is why we 
present all sample data in full.
To define the core age group, we decided on women 
eligible for mammography screening for breast cancer 
(50–69 years) because this is an implemented, systematic 
population-based screening programme in each of the 
five European countries, for which women in these coun-
tries receive an invitation letter every second year supple-
mented with information material.
All results are provided as absolute frequencies with 95% 
CIs. The non-parametric Wilcoxon test was used in order 
to perform within-group analyses of data collected from 
women comprising correct versus incorrect estimates of 
their perceived risk of developing breast cancer and also 
the variance in their misconceptions of mammography 
screening. All data were stored and analysed using IBM 
SPSS Statistics V.24.
Patient involvement
Patients were not involved in the design or conduct of the 
study. There is no plan to disseminate the results to study 
participants.
Data sharing
The full dataset is available to researchers via an applica-
tion to the FORECEE (4C) consortium group.
role of funding sources
The corresponding author had full access to all the data 
in the study and had final responsibility for the decision 
to submit for publication.
results
sample description
Of 3629 women invited, 848 did not respond, 197 were 
not eligible (duplicate listing, other strata than originally 
coded) and 492 entered the survey after respective quotas 
were filled. Of the 2092 who responded, 417 did not finish 
the survey, resulting in 1675 completed surveys. Using 
the American Association for Public Opinion Research 
response rate calculator, which incorporates a default 
method for estimating e (estimated proportion of cases of 
unknown eligibility that is eligible), the survey yielded a 
response rate of 61.4% (1675/[1675+417 + e(848)]) and 
a cooperation rate of 80.1% (1675/[1675+417]).
Of the 1675 surveys collected in total, 356 were completed 
in the Czech Republic, 335 in Germany, 323 in the UK, 
338 in Italy and 323 in Sweden. Across countries, the distri-
bution of age groups was: 40–49 (29.6%) years, 50–59 
(29.3%) years, 60–69 (29.5%) years and 70–75 (11.7%) 
and the distribution of educational levels was: low (27.8%), 
medium (48.8%) and high (23.5%). One hundred and four 
women reported a personal history of female cancer in the 
past and 25 were not sure if their diagnosis concerned a 
female cancer. Table 2 provides country-specific details on 
these characteristics. Note that based on the official distri-
bution of ISCED levels for each country, the proportion of 
respondents with low, medium and high levels of education 
differed across the five national samples in our study. Addi-
tional details on the match between the joint distribution of 
age and education within each of the national samples and 
the joint distribution of these two characteristics in each of 
the respective national populations are given in the online 
supplementary table 1).
Table 1 Actual age-specific risks of developing a certain female cancer within the next 10 years displayed for different age 
groups and for each of the four female cancers
Numbers of women who will develop cancer within the next 10 years…*
per 1000 women aged
45 years
per 1000 women aged
55 years
per 1000 women aged
65 years
per 1000 women aged
75 years
Breast cancer 21 30 35 33
Ovarian cancer 2 3 4 4
Cervical cancer 2 2 1 1
Endometrial cancer 2 5 6 6
*All age-specific cancer risks displayed in the table are based on the population-based cancer registration dataset of the German Centre for 
Cancer Registry Data within the Robert Koch Institute (www.krebsdaten.de), database query, 1 August 2016.
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Women’s knowledge of their age-specific cancer risk for 
female cancers
Among all women, 23.3% (rangecountry-specific correct responses: 
18.1%–29.3%) provided a correct estimate of their 
age-specific risk for breast cancer within the next 10 
years, 15.6% (range: 11.1%–23.6%) for ovarian cancer, 
6.8% (range: 3.4%–11.9%) for cervical cancer and 12.7% 
(range: 9.6%–19.4%) for endometrial cancer. A minority 
of women underestimated their age-specific cancer risks: 
17.5% for breast cancer, 2.8% for ovarian cancer, 1.4% 
for cervical cancer and 5.0% for endometrial cancer. Less 
than 1.7% considered their cancer risk for any of the four 
female cancers to be zero. The majority of women over-
estimated their age-specific risks: 59.2% for breast cancer, 
81.6% for ovarian cancer, 91.8% for cervical cancer and 
82.3% for endometrial cancer. The magnitude of over-
estimation across all women was 7-fold (medianoverestimations: 
200.0, rangeoverestimations: 35.0–950.0) for the age-specific risk 
for breast cancer, 16-fold (median: 50.0, range: 4.0–900.0) 
for ovarian cancer, 33-fold (median: 50.0, range: 3.0–999.0) 
for cervical cancer and 11-fold (median: 50.0, range: 
4.0–900.0) for endometrial cancer.
The highest proportion of correct estimates and the 
smallest proportion of overestimations of the age-specific 
risk for each of these cancers were observed among women 
in Germany, and the lowest proportion of correct estimates 
and highest proportion of overestimations among women in 
the UK (all country-specific estimates, table 3).
Women’s knowledge of mammography screening
Overall, 26.5% of women correctly knew that cancer 
screening such as mammography can result in both bene-
fits (eg, cancer-specific mortality reduction) and harms 
(eg, overdiagnosis), with the highest proportion of correct 
responses observed among women in Germany (43.3%) 
and the lowest proportion among women in Italy (13.3%) 
(table 4). Among women in the Czech Republic, Italy and 
Sweden, the highest proportion incorrectly believed that 
mammography screening prevents breast cancer: 59.7%, 
50.9% and 42.7%, respectively. For women in the UK, there 
was no clear difference in the proportion of women holding 
the correct or either of the two incorrect beliefs (table 4). 
Women who demonstrated accurate knowledge of their 
breast cancer risks were less likely to believe that mammog-
raphy screening would prevent cancer than women who 
demonstrated incorrect knowledge (z=−5.46, p<0.001, 
r=0.24).
breast cancer and screening knowledge of women in the core 
age group
Within each country, women in the core age group for 
mammography screening (50–69 years) displayed no 
better knowledge of their breast cancer risk than did 
women outside this group: 22.2% (95% CI 19.6 to 24.9) 
and 23.3% (21.3–25.4), respectively (table 3). Also, they 
showed no better understanding of the fact that mammog-
raphy can result in both benefits and harms than did 
women outside the core age group for mammography: 
only 26.9% (95% CI 24.2 to 29.8) and 26.5% (24.4–28.7), 
respectively, knew that mammography screening has both 
benefits and harms (table 4).
effect of an evidence-based patient leaflet on women's 
knowledge of cancer risks and cancer screening
After being presented with the intervention leaflet, 
the proportion of women correctly estimating their 
cancer-specific risks for each of the four female cancers 
notably increased: 30.7%, 37.1%, 27.0% and 36.7% for 
breast, ovarian, cervical and endometrial cancer, respec-
tively (table 3).
Table 2 Characteristics of study sample
Number of participants (%)
All countries
(n=1675)
Czech Republic
(n=356)
Germany
(n=335)
UK
(n=323)
Italy
(n=338)
Sweden
(n=323)
Age group (years)
  40–49 495 (29.6)  100 (28.1) 96 (28.7) 101 (31.3) 102 (30.2) 96 (29.7)
  50–59 490 (29.3) 90 (25.3)  109 (32.5) 101 (31.3) 96 (28.4) 94 (29.1)
  60–69 494 (29.5)  131 (36.8)  82 (24.5) 82 (25.4) 101 (29.9)  98 (30.3) 
  70–75 196 (11.7) 35 (9.8) 48 (14.3) 39 (12.1) 39 (11.5) 35 (10.8)
Education (ISCED)
  High 393 (23.5) 52 (14.6) 65 (19.4)  116 (35.9)  43 (12.7) 117 (36.2)
  Medium 817 (48.8) 256 (71.9) 207 (61.8)  111 (34.4)  112 (33.1) 131 (40.6)
  Low 465 (27.8) 48 (13.5) 63 (18.8) 96 (29.7) 183 (54.1) 75 (23.2)
Personal history of female cancer
  Yes 104 (6.2) 20 (5.6) 23 (6.9) 19 (5.9)  20 (5.9) 22 (6.8)
  Unknown 25 (1.5) 6 (1.7) 1 (0.3) 4 (1.2) 7 (2.1) 7 (2.2) 
  No 1546 (92.3) 330 (92.7)  311 (92.8) 300 (92.9)  311 (92.0)  294 (91.0) 
ISCED, International Standard Classification of Education.
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The proportion of women who overestimated their 
cancer risks declined by 38.7%, 38.1%, 26.2% and 39.5% 
for breast, ovarian, cervical and endometrial cancer, 
respectively (table 3). Likewise, the magnitude of over-
estimations decreased across countries for breast cancer 
from 7-fold to 3-fold (medianoverestimations: 100.0, rangeoverestima-
tions: 33.0–900.0), for ovarian cancer from 16-fold to 6-fold 
(median: 20.0, range: 4.0–900.0), for cervical cancer from 
33-fold to 6-fold (median: 10.0, rangeoverestimations: 3.0–950.0) 
and for endometrial cancer from 11-fold to 4-fold (median: 
21.0, range: 4.0–950.0) (figure 1).
Furthermore, women’s awareness that mammog-
raphy screening can result in both benefits and harms 
significantly increased by 17.0%–35.3% across countries 
(table 4). At the same time, the proportion of women 
holding one of the two incorrect beliefs concerning 
mammography screening decreased across countries by 
4.9%–20.8% (table 4).
Although improvements in knowledge about female 
cancer risks and mammography were significant within 
each national sample, the actual extent of improvements 
varied across countries, with the largest improvements 
in estimates of the four female cancer risks observed in 
the UK (32.2%–43.0%) and Sweden (31.9%–44.3%) 
and the smallest in the Czech Republic (21.6%–33.3%) 
and Italy (21.3%–31.1%) (table 3). Women from the 
UK further showed the largest improvement in a correct 
understanding of mammography screening (35.3%), 
whereas that improvement in the other four countries 
did not significantly differ (Sweden: 17.0%, Italy: 20.1%, 
Germany: 21.2% and Czech Republic: 21.9%) (table 4).
DIsCussIOn
In our survey of 1675 women in five European countries, 
59.2%–91.8% overestimated their age-specific risks for 
four female cancers by 7-fold to 33-fold. Over 70% did 
not know that mammography screening has both bene-
fits and harms but instead believed that it has only bene-
fits or can even prevent breast cancer. Those eligible for 
population-based mammography screening programmes 
and regularly invited to participate by health authorities 
demonstrated no better understanding of these facts. 
Women with incorrect knowledge of their breast cancer 
risk were particularly likely to believe that mammography 
screening can prevent the onset of breast cancer.
Where do these misunderstandings originate? Although 
we did not actively investigate potential reasons, findings 
from other studies15 24 suggest that insufficient commu-
nication of risks by health-specific sources can be influ-
ential. Few leaflets, letters of invitation to screenings and 
health websites use absolute statistics to explain the actual 
risk of cancer and the potential benefits and harms of 
screening.24–28 Instead, they often use relative statistics, life-
time incidences, 5-year survival rates or no numbers at all, 
all of which contribute to women seriously overestimating 
their own cancer risk and the benefit of screening.29–33 
Also, European health information on mammography C
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cancer screening is often unbalanced and has been criti-
cised by health authorities (eg, National Board of Health 
and Welfare in Sweden34 and Federal Joint Committee in 
Germany35) for insufficiently informing the public. As a 
consequence, the Federal Joint Committee in Germany 
passed a resolution in 2015 to standardise patient infor-
mation on mammography screening by basing it on the 
guidelines for evidence-based health information; all 
women invited to the programme have since been given 
this new information.35 For other screening programmes, 
nationwide standardised, evidence-based information for 
women does not exist. Delivering adequate information 
is thus mainly left to gynaecologists offering screening for 
female cancers. However, considering that past studies 
found physicians to be susceptible to framing effects 
created by using relative as opposed to absolute risk reduc-
tion formats,36–40 have difficulty calculating the positive 
predictive value of tests41–44 or misunderstand screening 
statistics,45 46 it remains an open question as to whether 
women will receive the requisite information needed to 
make an informed choice.
From a positive point of view, our findings demonstrate 
that the provision of balanced, evidence-based health 
information substantially improves women’s knowledge 
of their age-specific cancer risks and their understanding 
of mammography screening: overestimations of their own 
cancer risk declined by 26.2–39.5 percentage points and the 
number of women who consequently knew that mammog-
raphy can result in benefits and harms doubled. Taking 
into account the level of education (as measured by the 
ISCED), we observed significant improvements—although 
to a different extent—across all questions among women 
with a low, medium and high ISCED rating, suggesting 
that regardless of education level, women will profit from 
balanced health information (online supplementary table 
2), and even though the national samples in our study 
differed in the distribution of education levels, reflecting 
real differences in the distribution of this characteristic 
Figure 1 European women’s estimates of their age-specific risks of breast, ovarian, cervical and endometrial cancer before 
and after reading the evidence-based leaflet with standard error (marked in dark grey). The dotted line marks the accepted area 
of correct estimates for each of the cancer risks. 
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in the respective country-specific base population, we 
observed no relevant systematic differences in knowledge 
of cancer risk and understanding of mammography before 
intervention or systematic differences in improvements of 
that knowledge and understanding after intervention.
limitations
One needs to be mindful of some limitations when consid-
ering our study’s findings. First, we chose a ±50% margin of 
error for the age-specific cancer risks as a proxy denoting 
a correct estimate. Since the actual risk of breast cancer is 
approximately 10 times higher than the risks of the other 
three cancer types, the rule applied made it more likely 
that women’s responses were rated correct for their esti-
mated breast cancer risk than for the other three cancer 
types. Second, our study did not assess whether the degree 
of overestimating one’s cancer risk or the improved 
knowledge observed after the intervention actually trans-
late into any behavioural changes, for example, lower 
or higher participation rates in screening. Other studies 
from the USA47 found, however, that overestimating one’s 
own cancer risk is associated with largely overestimating 
the mortality reduction of cancer screening, which in turn 
has been found in further studies to be associated with 
higher participation rates.17 48 Third, the cross-sectional 
design of the study prevented us from assessing durability 
of improvements in knowledge. We thus are not able to 
judge whether women maintain over a longer run the 
improvements in knowledge we found in our study. Fourth, 
we cannot rule out the existence of non-respondents’ bias. 
Although we achieved a reasonable response rate and strat-
ified the sample to match women’s characteristics for age 
and education in our sample to the general population at 
survey completion, we cannot exclude the likelihood that 
women with higher cancer risks due to close family history 
or a greater interest in the topic of cancer and screening 
were more likely to respond to our survey, which might 
have influenced our results and limit the generalisability 
of our results. However, analyses excluding women who 
reported a personal history of female cancer in our study 
did not change any of the results reported here. Fifth, 
we can only speculate why women from different Euro-
pean countries substantially varied in their knowledge on 
female cancer risks and mammography in the first place. 
A comparison of country-specific health information on 
mammography provided to women in these five Euro-
pean showed a considerable variance in standardisation 
(ie, women within the same country receive/d not receive 
identical information, information is given/not given on 
i. age-specific cancer prevalence, ii.benefits and harms of 
screening and on iii. positive/negative predictive value of 
test). To what extent these differences in health informa-
tion explain our findings needs to be studied in greater 
detail in future studies.
COnClusIOn
Despite these limitations, our study suggests that a 
large proportion of women in five European countries 
are highly uninformed about their cancer risks and 
mammography screening. In these cases, informed 
decision making about cancer screening is not possible. 
From a definitive perspective, the present study shows 
that a correctly perceived cancer risk is positively asso-
ciated with women’s expectations of cancer screening 
and that evidence-based information has the potential to 
improve women’s understanding of their cancer risks and 
screening facts. These findings should encourage health 
authorities to continue their endeavours to implement 
evidence-based, standardised cancer health information.
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